Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc.

NAUT·NASDAQ

$2.71

+0.93%
HealthcareBiotechnology

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

At a Glance

Live Snapshot
Market Cap$343.75M
EPS-0.4700
P/E Ratio-5.76
Earnings Date08/04/2026

naut

Stock Based Compensation

Last Annual Value

6.84M

3-Year CAGR

-13%

5-Year CAGR

79%

10-Year CAGR

%

Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Competitors Analysis of Stock Based Compensation

NAUT · NASDAQ
CompanyStock Based Compensation
CAGR 3Y
CAGR 5Y
CAGR 10Y
6.84M
-17.4%-2.9%N/A 
13.05M
-5.2%34.6%N/A
ZURA logo
Zura Bio Limited
NASDAQ:ZURA
12.33M
8.5%N/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
9.75M
12.6%-0.8%N/A
25.41M
-9.8%-2.6%26.1%
6.45M
8.9%27.6%N/A
0.00
N/AN/AN/A
AGEN logo
Agenus Inc.
NASDAQ:AGEN
17.39M
-8.7%-2.3%2.8%
2.09M
-21.7%-16.6%N/A
1.33M
7.3%21.1%N/A
6.42M
137.6%57.9%N/A
Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. Fair Value Envelope

NAUT · NASDAQ

Our analysis suggests that NAUT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.705, this represents a potential HIDDEN relative to our calculated worth for Nautilus Biotechnology, Inc..

Intrinsic Value
Current Price: $2.705